Drug Trial Radar · NCT06378229
Psilocybin for Hospitalized Patients with Treatment-resistant Depression
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
Mar 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- University Hospital, GhentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Filament Health Corp.
- First posted
- Apr 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and feasibility of performing psilocybin-assisted psychotherapy in patients hospitalized for treatment-resistant depression.
Conditions
- Treatment Resistant Depression
Interventions
PsilocybinDrug
A psychedelic drug found in certain mushrooms. It will be in a capsule of 25mg psilocybin (PEX010).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and type of Treatment-Emergent Adverse EventsTime frame: 18 weeks
- Columbia-Suicide Severity Rating Scale (C-SSRS)Time frame: 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.